Enrich Biosystems

Executive Summary

Enrich Biosystems, based in Cambridge, Massachusetts, is a private biotechnology company advancing precision cell analysis through its proprietary TROVO platform. The technology combines microgel lithography with AI-powered analysis to enable high-throughput, functional screening and live-cell retrieval. Unlike traditional methods that rely on surface markers, TROVO allows researchers to screen cells based on functional output, making it particularly valuable for cell therapy and biologics development. Founded in 2016, the company addresses a critical bottleneck in therapeutic discovery by accelerating the identification of high-performing cells, potentially reducing timelines for drug development and improving success rates in preclinical studies. Enrich Biosystems is positioned at the intersection of diagnostics and proteomics, with its platform serving as a key enabler for functional genomics and phenotypic screening. Although the company has not disclosed its total funding or valuation, its innovative approach has garnered attention in the biotech community. The TROVO system’s ability to integrate high-throughput functionality with single-cell resolution offers a competitive advantage over existing technologies. As the demand for more efficient cell engineering tools grows, Enrich Biosystems is poised to capture market share in the rapidly expanding cell therapy and bioproduction sectors. Future growth will depend on successful commercial adoption, strategic partnerships, and continued technological enhancements.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-20 pharmaceutical company for cell therapy screening60% success
• Q4 2026Series B funding round of $30M+ to expand commercial deployment50% success
• Q2 2026Launch of new TROVO application module for antibody discovery70% success